- [1]Li Yuanjian, Ma Jinan, Peng Liubao, Wan Xiaomin.Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.Cancer, 123 (14) : 2634-2641.
- [2]Peng Liubao, Zhang Yucong, Zeng Xiaohui, Tan Chongqing, Luo Xia, Wan Xiaomin.First-Line Atezolizumab in Addition to Bevacizumab Plus Chemotherapy for Metastatic, Nonsquamous Non–Small Cell Lung Cancer: A United States–Based Cost-Effectiveness Analysis.Cancer, 125 (20) : 3526-3534.
- [3]Peng Liubao, Zeng Xiaohui, Tan Chongqing, Zhang Yucong, Wan Xiaomin.First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis[J].JAMA Oncology, 5 (4) : 491-496.
| |